NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable. Herein we report results of a phase I/II trial to evaluate the safety and activity of autologous T-cells engineered to express an affinity-enhanced T-cell receptor (TCR) recognizing a naturally processed peptide sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Rapoport, Aaron P., Stadtmauer, Edward A., Binder-Scholl, Gwendolyn K., Goloubeva, Olga, Vogl, Dan T., Lacey, Simon F., Badros, Ashraf Z., Garfall, Alfred, Weiss, Brendan, Finklestein, Jeffrey, Kulikovskaya, Irina, Sinha, Sanjoy K., Kronsberg, Shari, Gupta, Minnal, Bond, Sarah, Melchiori, Luca, Brewer, Joanna E., Bennett, Alan D., Gerry, Andrew B., Pumphrey, Nicholas J., Williams, Daniel, Tayton-Martin, Helen K., Ribeiro, Lilliam, Holdich, Tom, Yanovich, Saul, Hardy, Nancy, Yared, Jean, Kerr, Naseem, Philip, Sunita, Westphal, Sandra, Siegel, Don L., Levine, Bruce L., Jakobsen, Bent K., Kalos, Michael, June, Carl H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529359/
https://www.ncbi.nlm.nih.gov/pubmed/26193344
http://dx.doi.org/10.1038/nm.3910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529359/
https://www.ncbi.nlm.nih.gov/pubmed/26193344
http://dx.doi.org/10.1038/nm.3910

Ejemplares similares